Business
Resverlogix Announces Financing
Resverlogix Announces Financing
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\n Jun. 2, 2010 (Canada NewsWire Group) -- /THIS PRESS RELEASE IS NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH US NEWSWIRE SERVICES./\n\nTSX Exchange Symbol: RVX\n\n Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces today that it has entered into an agency agreement for an offering of units, each comprised of one common share and 0.4 of a common share purchase warrant, at a price of CDN $3.30 per unit. Each whole common share purchase warrant entitles the holder to acquire one common share of Resverlogix upon payment of CDN $4.00, exercisable for a four year period commencing on the closing date of the offering. The offering is being conducted by Bloom Burton & Co. and Haywood Securities Inc. The offering is to be effected in each of the Canadian provinces of British Columbia, Alberta and Ontario by way of a prospectus supplement to Resverlogix's base shelf prospectus dated April 20, 2010.\nThe Company expects that this transaction will close on or about June 8, 2010, subject to satisfaction of customary closing conditions, including the receipt of all necessary regulatory and stock exchange approvals. The securities are being offered in each of the Canadian provinces of British Columbia, Alberta and Ontario by way of a prospectus supplement to Resverlogix's base shelf prospectus, dated April 20, 2010.\n\nAbout Resverlogix Corp.\n\nResverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas(TM) PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.\n\nThis news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to, the current and/or future financings, research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular dise...